Literature DB >> 24690638

Exogenous lytic activity of SPN9CC endolysin against gram-negative bacteria.

Jeong-A Lim1, Hakdong Shin, Sunggi Heu, Sangryeol Ryu.   

Abstract

Concerns over drug-resistant bacteria have stimulated interest in developing alternative methods to control bacterial infections. Endolysin, a phage-encoded enzyme that breaks down bacterial peptidoglycan at the terminal stage of the phage reproduction cycle, is reported to be effective for the control of bacterial pathogenic bacteria. Bioinformatic analysis of the SPN9CC bacteriophage genome revealed a gene that encodes an endolysin with a domain structure similar to those of the endolysins produced by the P1 and P22 coliphages. The SPN9CC endolysin was purified with a C-terminal oligo-histidine tag. The endolysin was relatively stable and active over a broad temperature range (from 24°C to 65°C). It showed maximal activity at 50°C, and its optimum pH range was from pH 7.5 to 8.5. The SPN9CC endolysin showed antimicrobial activity against only gram-negative bacteria and functioned by cutting the glycosidic bond of peptidoglycan. Interestingly, the SPN9CC endolysin could lyse intact gram-negative bacteria in the absence of EDTA as an outer membrane permeabilizer. The exogenous lytic activity of the SPN9CC endolysin makes it a potential therapeutic agent against gram-negative bacteria.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24690638     DOI: 10.4014/jmb.1403.03035

Source DB:  PubMed          Journal:  J Microbiol Biotechnol        ISSN: 1017-7825            Impact factor:   2.351


  23 in total

1.  Expanding the Database of Signal-Anchor-Release Domain Endolysins Through Metagenomics.

Authors:  Marco Túlio Pardini Gontijo; Mateus Pereira Teles; Pedro Marcus Pereira Vidigal; Marcelo Brocchi
Journal:  Probiotics Antimicrob Proteins       Date:  2022-05-07       Impact factor: 4.609

Review 2.  Antimicrobial bacteriophage-derived proteins and therapeutic applications.

Authors:  Dwayne R Roach; David M Donovan
Journal:  Bacteriophage       Date:  2015-06-23

3.  DUF3380 Domain from a Salmonella Phage Endolysin Shows Potent N-Acetylmuramidase Activity.

Authors:  Lorena Rodríguez-Rubio; Hans Gerstmans; Simon Thorpe; Stéphane Mesnage; Rob Lavigne; Yves Briers
Journal:  Appl Environ Microbiol       Date:  2016-07-29       Impact factor: 4.792

4.  Expression of a Peptidoglycan Hydrolase from Lytic Bacteriophages Atu_ph02 and Atu_ph03 Triggers Lysis of Agrobacterium tumefaciens.

Authors:  Hedieh Attai; Jeanette Rimbey; George P Smith; Pamela J B Brown
Journal:  Appl Environ Microbiol       Date:  2017-11-16       Impact factor: 4.792

5.  Multiple-site mutations of phage Bp7 endolysin improves its activities against target bacteria.

Authors:  Can Zhang; Yuanchao Wang; Huzhi Sun; Huiying Ren
Journal:  Virol Sin       Date:  2015-10-16       Impact factor: 4.327

Review 6.  Enzybiotics: Enzyme-Based Antibacterials as Therapeutics.

Authors:  Dorien Dams; Yves Briers
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

7.  Codon reassignment to facilitate genetic engineering and biocontainment in the chloroplast of Chlamydomonas reinhardtii.

Authors:  Rosanna E B Young; Saul Purton
Journal:  Plant Biotechnol J       Date:  2015-10-15       Impact factor: 9.803

8.  Antibacterial Activity of Stenotrophomonas maltophilia Endolysin P28 against both Gram-positive and Gram-negative Bacteria.

Authors:  Hongling Dong; Chaoyang Zhu; Jingyi Chen; Xing Ye; Yu-Ping Huang
Journal:  Front Microbiol       Date:  2015-11-24       Impact factor: 5.640

9.  Antibacterial Activity of a Novel Peptide-Modified Lysin Against Acinetobacter baumannii and Pseudomonas aeruginosa.

Authors:  Hang Yang; Mengyue Wang; Junping Yu; Hongping Wei
Journal:  Front Microbiol       Date:  2015-12-22       Impact factor: 5.640

10.  Enhanced Antibacterial Activity of Acinetobacter baumannii Bacteriophage ØABP-01 Endolysin (LysABP-01) in Combination with Colistin.

Authors:  Rapee Thummeepak; Thawatchai Kitti; Duangkamol Kunthalert; Sutthirat Sitthisak
Journal:  Front Microbiol       Date:  2016-09-07       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.